BioCentury | Feb 17, 2017
Company News

AMAG, Endoceutics deal

...Endoceutics granted AMAG exclusive, U.S. rights to commercialize Intrarosa prasterone. The product is approved to treat...
...shared equally and capped at $20 million for AMAG. The once-daily vaginal insert delivers localized prasterone...
BioCentury | Nov 17, 2016
Clinical News

Intrarosa regulatory update

...FDA approved an NDA for Intrarosa prasterone from Endoceutics to treat moderate to severe dyspareunia, a...
...of vulvar and vaginal atrophy (VVA), in postmenopausal women. The once-daily vaginal insert delivers localized prasterone...
...vaginal cells and tissue. Endoceutics Inc. , Quebec City, Quebec Product: Intrarosa prasterone Business: Genitourinary Julian Zhu Intrarosa prasterone Endoceutics...
BioCentury | Jun 19, 2008
Cover Story

Moving Velcade into Lupus

...Genelabs Technologies Inc. (NASDAQ:GNLB)/Genovate Biotechnology Co. Ltd./Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA)/Watson Pharmaceuticals Inc. (NYSE:WPI) Prestara prasterone...
BioCentury | Dec 3, 2007
Company News

Genelabs, Mitsubishi Tanabe Pharma deal

...2004 deal under which Mitsubishi Tanabe had exclusive Japanese rights to GNLB's Prestara prasterone ( Anastar...
BioCentury | Sep 27, 2007
Financial News

Genelabs raises $23.7 million

...it will not use the funds to run an additional Phase III trial of Prestara prasterone...
...will seek to secure non-dilutional or minimally dilutional financing, including potential partnerships, to fund another Prestara...
BioCentury | Apr 9, 2007
Clinical News

Prestara prasterone regulatory update

...Prestara vs. placebo over 12 months in 500 women with acute systemic lupus erythematosus (SLE). Prestara...
...Tokyo:4508; Osaka:4508), Osaka, Japan Teva Pharmaceutical Industries Ltd. (TEVA), Jerusalem, Israel Product: Prestara prasterone ( GL701...
BioCentury | May 15, 2006
Product Development

SLE pipeline

...4 ds-oligonucleotides that bind to double-stranded DNA (ds-DNA) on B cells Ph III Genelabs Prestara prasterone...
BioCentury | May 15, 2006
Product Development

Surviving cancer

...composed of four ds-oligonucleotides that bind to double-stranded DNA (ds-DNA) antibodies on B cells. Prestara prasterone...
...Study GBL03-00 in 2005. Also, GNLB (Redwood City, Calif.) pulled its MAA for Prestara ( Anastar...
...to pay for it. At March 31, the company had about $7.5 million in cash. Prestara...
BioCentury | Aug 22, 2005
Clinical News

Prestara prasterone: Preliminary Phase III data

...6-month, double-blind, placebo-controlled, U.S. and Mexican Phase III GL02-01 trial showed that 200 mg once-daily Prestara...
...the 155 patients in GL02-01, 115 enrolled in GL03-01 and received 100 or 200 mg Prestara...
...Ltd. , Hsinchu, Taiwan Tanabe Seiyaku Co. Ltd. , Osaka, Japan Product: Prestara prasterone ( GL701...
BioCentury | Jun 27, 2005
Clinical News

Prestara prasterone regulatory update

...FDA confirmed that Orphan Drug designation for Prestara to prevent bone mineral density loss in systemic...
...SLE) patients on glucocorticoids qualifies under the original Orphan Drug designation received by the company. Prestara...
...Watson Pharmaceuticals Inc. (WPI), Corona, Calif. Tanabe Seiyaku Co. Ltd. , Chuo-ku, Japan Product: Prestara prasterone...
Items per page:
1 - 10 of 108